Study offers insights into who’s at risk for long COVID among immunocompromised patients

PD-1/PD-L1 inhibitors are standard of care in advanced and metastatic non-small cell lung cancer (NSCLC), and several studies reported at the American Society of Clinical

No­vo Nordisk has inked an up to $1.46 bil­lion deal with the biotech Neo­morph to de­vel­op “mol­e­c­u­lar glues,” a field that’s see­ing a flur­ry of

As a stricter gatekeeper to nonculprit lesion intervention in people with acute myocardial infarction (MI) going for complete revascularization, fractional flow reserve (FFR) guidance was